| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 7.2K | 1.7% | 24.3% |
| Total Income | 7.3K | 2.0% | 25.1% |
| Expenditure | 5.3K | 4.0% | 12.3% |
| PBT | 1.5K | 24.2% | 42.1% |
| Net Profit | 1.2K | 20.5% | 37.5% |
| OPM | 25.61% | 7.61pp | 13.83pp |
| NPM | 16.21% | 4.59pp | 1.46pp |
| EPS | 25.74 | 20.5% | 37.3% |
Lupin Ltd Reports Strong Q3 FY2026 Results with 26.4% YoY Sales Growth
12 Feb 2026 · 12 Feb, 10:53 pm
Summary
Pharma major Lupin Limited reported its financial performance for the quarter ending December 31, 2025. The company's sales grew by 26.4% YoY and EBITDA margin increased by 840 bps YoY.
Key Highlights
- 1
Q3 FY2026 sales: INR 71,005 Mn
- 2
Q3 FY2026 EBITDA: INR 23,766 Mn
- 3
Q3 FY2026 EBITDA margin: 33.5%
- 4
Q3 FY2026 Adjusted PBT: INR 15,220 Mn
- 5
Q3 FY2026 PAT: INR 11,805 Mn
- 6
Gross profit: INR 52,224 Mn
- 7
Gross margin: 73.5%
- 8
Personnel cost: INR 11,433 Mn
- 9
Manufacturing and other expenses: INR 19,366 Mn
- 10
Investment in R&D: INR 5,352 Mn
Management Comments
Mr. Nilesh Gupta
We are happy to deliver another quarter of strong growth led by our highest ever quarterly sales in the US and double-digit growth in India and all other regions. We are on track to deliver a strong close to FY26.
Informational and educational content only. Not investment advice.